Y-mabs Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Y-mAbs Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and update the exhibit list, while also revising its non-employee director compensation policy.
10-K: Y-mAbs Therapeutics Reports 2024 Results, Focuses on DANYELZA and Radiopharmaceutical Platform
Y-mAbs Therapeutics details its 2024 financial performance and strategic shift towards expanding DANYELZA's market presence and advancing its radiopharmaceutical platform.
Y-mAbs Therapeutics, Inc. details its financial status, strategic restructuring, and pipeline advancements in its annual 10-K filing, highlighting its focus on DANYELZA and SADA PRIT technology.